About seller
Background Healthcare professional burnout has reached epidemic proportions, with downstream effects on personal and patient health and on our institutions. Solutions lie in the domains of work culture, operational efforts, and personal strategies. Objectives To evaluate the impact of a 5-day mind-body medicine professional training program on burnout and quality of life. Methods We conducted pre- and postevaluation of a mind-body medicine skills training for healthcare professionals on 6 wellness domains using 2 validated instruments the Maslach Burnout Inventory and the Professional Quality of Life Survey. Results There was a statistically significant improvement in changes in emotional exhaustion, depersonalization, personal accomplishment, compassion satisfaction, burnout, and secondary traumatic stress which was sustained at 12 months. Largest relative improvements occurred in emotional exhaustion and depersonalization, 22% and 21%, respectively. Conclusion In addition to providing an important patient care skill set, mind-body medicine training may be an effective way to mitigate burnout and improve healthcare professional well-being. © The Author(s) 2020.This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS, Inc. (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation, education and on-site risk management audits, and other resources offered to health care providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company. Other risk management consulting companies or insurance carriers may provide different advice, and readers should take this into consideration. AdipoRon The information in this column does not constitute legal advice. For legal advice, contact your personal attorney. Note The information and recommendations in this article are applicable to physicians and other health care professionals so "clinician" is used to indicate all treatment team members. All rights reserved.Anxiety disorders are the most prevalent psychiatric disorders among youth, with prevalence rates ranging from 25 to 32 percent. These disorders are under-recognized and often undertreated in this population. Anxiety disorders in youth exhibit a chronic and persistent course of symptoms with a higher risk of comorbidities, functional impairment, and worsening of severity. The early recognition and treatment of anxiety disorders in children and adolescents are vital for better long-term outcomes. This article summarizes the evidence-based pharmacologic treatments for mixed anxiety disorders including generalized anxiety disorder, social anxiety disorder, and separation anxiety disorder in children and adolescents based on case reports, case series, open-label trials, and randomized, controlled trials. All rights reserved.Children who are inadequately treated for depression often experience greater dysfunction. Problems can include conduct disorders, substance abuse, physical illness, and poor performance at school, work, or in psychosocial contexts. Depression can lead to a greater risk of suicide. Suicide is the third most common cause of death among adolescents, with more than 500,000 attempts made by children each year. Suicide is the third most frequent cause of death among young people ages 10 to 19 years old. Thus, proper treatment is important. Major depressive disorder in adolescents is often followed by frequent recurrences in adulthood. Imaging studies document underactivity in the left dorsolateral prefrontal cortex in subjects suffering from depression. Activation of the brain with high-frequency transcranial magnetic stimulation increases neuronal excitability and induces the growth of new connections. Though larger, randomized, controlled trials with more patients and longer follow-up are needed, the favorable side effect profile and efficacy of TMS seen so far in the literature support the use of TMS as a therapeutic intervention in children and adolescents with depression. All rights reserved.Atypical antipsychotics, used to treat patients with schizophrenia, focus on dopamine-2 (D2) plus serotonin-2A (5-HT2A) receptor antagonism and currently carry different degrees of certain adverse effects. Brexpiprazole is a new serotonin-dopamine receptor modulator that acts as a partial agonist at the 5-HT1A and D2 receptors. In patients who were either introduced to brexpiprazole because of nonadherence to traditional medications or were switched from apripiprazole, olanzapine, or paliperidone, the impact of brexpiprazole on different parameters was evaluated. Ultimately, it was found that brexpiprazol treatment displayed a low propensity to influence metabolic parameters (lipids and glucose) and minimal impact on prolactin levels. Further prospective and longer follow-up studies involving larger groups of subjects are required. All rights reserved.Background The Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDSUPDRS), Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT), Mayo Sleep Questionnaire, Epworth Sleepiness Scale, and Neuropsychiatric Inventory Questionnaire (NPI-Q) are validated instruments for assessing signs and symptoms of Parkinson's disease (PD). Objective We sought to determine whether responses on the MDS-UPDRS correlate with responses to other scales used in patients with PD. Design Study subjects were enrolled in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND). Participants were selected if they had completed all scales within a one-month window. Spearman's rank correlation coefficients were calculated. Results A total of 96 eligible subjects were identified. High correlation (r-values) was found between the SCOPA-AUT and MDS-UPDRS excessive saliva (0.73; p less then 0.001), constipation (0.62; p less then 0.001), and swallowing (0.59; p less then 0.001) questions. The r-values for the NPI-Q and MDS-UPDRS depression and anxiety questions were 0.